Last week, the Biotechnology Value Fund (BVF) proposed that Celera Corp. separate its low margin diagnostics business from its potentially high-margin drug royalty stream.
The Biotechnology Value Fund (BVF), a historically activist investor group, revealed in a 13-D filing Tuesday the reason for its recent interest in diagnostics firm Celera Corp.: BVF wants Celera to spin out its royalty interest in Merck & Co. Inc.'s Phase III osteoporosis drug, odanacatib. (BioWorld Today)
The experts at Ernst & Young previously predicted pharma's acquisition tastes in 2010 would run toward international firms, particularly those that provide a toehold in emerging markets, and players in the fragmented branded generics space, which is ripe for consolidation. (BioWorld Today)
